Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3317-3318

  Hartmann, Holger ^a   Müller, Judith ^a   Marschner, Norbert ^b  

^a iOMEDICO   (Germany)

^b Praxis für Interdisziplinäre Onkologie und Hämatologie Freiburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

CANCER CHEMOTHERAPY; CLINICAL CLASSIFICATION; COLORECTAL CANCER; COMPARATIVE STUDY; DEMOGRAPHY; DRUG EFFICACY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LETTER; MEDICARE; OVERALL SURVIVAL; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MEDICARE;

EID: 84866525132     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.3409     Document Type: Letter

References (4)

1. Meyerhardt JA, Li L, Sanoff HK, et al: Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 30:608-615, 2012
2. National Comprehensive Cancer Network: New treatment options featured in NCCN colorectal clinical practice guidelines. http://www.nccn.org/about/news/ newsinfo.asp?NewsID=41
3. Grothey A, Sugrue MM, Purdie DM, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334, 2008
4. Quigley J, Moseley A, Bule W: Utilization of bevacizumab therapy in metastatic colorectal cancer patients with financial need (Medicare and Medicaid), based upon NCCN guidelines. 2006 Gastrointestinal Cancers Symposium, San Francisco, CA, January 26-28, 2006 (abstr 246)